6-bromoferulic acid | 70842-38-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 6-bromoferulic acid
• 英文别名: 6-BFA；6-bromo-4-hydroxy-3-methoxy-trans-cinnamic acid；6-Brom-4-hydroxy-3-methoxy-trans-zimtsaeure；3-(2-Bromo-4-hydroxy-5-methoxyphenyl)prop-2-enoic acid；(E)-3-(2-bromo-4-hydroxy-5-methoxyphenyl)prop-2-enoic acid
• CAS: 70842-38-5
• 化学式: C₁₀H₉BrO₄
• 分子量: 273.083
• InChiKey: ZCMBFUYSGHEJQS-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-乙酰氧基-2-溴-5-甲氧基苯甲醛 在 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 生成 6-bromoferulic acid
  参考文献：
  名称：

  Characterization of 6‐bromoferulic acid as a novel common‐use matrix for matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry

  摘要：

  RationaleFerulic acid (FA) is a standard matrix used for analyzing proteins. In this study, the ability of a halogenated FA to serve as an effective MALDI matrix was investigated. Various halogenated FAs were synthesized, and the characteristics and performance of each were compared with those of the standard matrices α‐cyano‐4‐hydroxycinnamic acid (CHCA) and 2,5‐dihydrobenzoic acid (DHBA).MethodsThe abilities of 6‐bromoferulic acid (6‐BFA), ferulic acid (FA), and eight other halogenated FA derivatives to ionize eight synthetic peptides were examined. Absorption measurements, MM2 structure optimizations, and proton affinity (PA) calculations were also performed for 6‐BFA and FA. The suitabilities of these compounds as matrices for matrix‐assisted laser desorption/ionization (MALDI) for lipids, sugar chains, polymers, cyanocobalamin, synthetic peptides, and tryptic peptides originating from two types of serum proteins were also tested.ResultsThe 6‐position of FA was found to be the best site for introducing a bromine because the generated compound allowed facile detection of cyanocobalamin and several peptides. 6‐BFA exhibited good sensitivity for large peptides (3–5 kDa) and peptides containing acidic amino acids or proline. 6‐BFA was also shown to be a suitable matrix for tandem mass spectrometry (MS/MS) analysis when using MALDI time‐of‐flight (TOF) mass spectrometry (MS) with a quadrupole ion trap (QIT) system.ConclusionsThe properties of 6‐BFA as a MALDI matrix differed from those of DHBA and CHCA. 6‐BFA appears to be a useful matrix for de novo sequencing using MALDI‐QIT‐TOF‐MS.

  DOI：

  10.1002/rcm.8636

文献信息

• PHENYLPROPIONATE COMPOUND, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF
  申请人：SUZHOU PHARMAVAN CO., LTD

  公开号：US20200331842A1

  公开（公告）日：2020-10-22

  Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.

  本发明提供了一种苯丙酸酯化合物及其制备方法和应用。该苯丙酸酯化合物的结构如化学式I所示。本发明的苯丙酸酯化合物、药用可接受的盐、溶剂合物、前药、互变异构体或立体化学异构体或该化合物的药物组合物提供了改进的抗炎和抗血小板效果，并且同时提供了治疗的延长时间窗口，无明显副作用，安全有效，在抗凝血、抗炎和治疗脑卒中药物中适用，并具有广泛的应用前景。
• Methods and reagents for the treatment of metabolic disorders
  申请人：Lee S. Margaret

  公开号：US20060069161A1

  公开（公告）日：2006-03-30

  The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

  本发明的特点是用于治疗糖尿病和肥胖症等代谢性疾病的组合物、方法和试剂盒。
• Webster, American Journal of Pharmacy and the Sciences Supporting Public Health (1937-1978), 1940, vol. 112, p. 291,293, 294
  作者：Webster

  DOI：——

  日期：——
• EP1781303A4
  申请人：——

  公开号：EP1781303A4

  公开（公告）日：2008-07-02
• METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：CombinatoRx, Incorporated

  公开号：EP1781303A1

  公开（公告）日：2007-05-09